FutureChem Co

FutureChem Co FCF/Debt

The Free Cash Flow to Debt Ratio of FutureChem Co (220100.KQ) as of Oct 23, 2026 is -50.10 %. In the previous year, Free Cash Flow to Debt Ratio was -166.79 % — a change of -69.96% (higher).

FCF/Debt

-50.10 %

YoY

-69.96%

Last updated:

Free Cash Flow to Debt Ratio of FutureChem Co is 2024 -50.10 % . Free Cash Flow to Debt Ratio of FutureChem Co was 2023 -166.79 % . It decreases by -69.96% higher compared to the previous year.

The FutureChem Co FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2017
-180.03 KRW
Jan 1, 2018
-27.84 KRW
Jan 1, 2019
-26.98 KRW
Jan 1, 2020
-25.18 KRW
Jan 1, 2021
-60.80 KRW
Jan 1, 2022
-88.22 KRW
Jan 1, 2023
-166.79 KRW
Jan 1, 2024
-50.10 KRW
The FutureChem Co FCF/Debt history
YEARFCF/DebtYoY
-50.10 %-69.96%
-166.79 %+89.07%
-88.22 %+45.11%
-60.80 %+141.41%
-25.18 %-6.66%
-26.98 %-3.09%
-27.84 %-84.54%
-180.03 %-39.94%
-299.76 %+3,581.53%
-8.14 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

FutureChem Co Stock analysis

What does FutureChem Co do? FutureChem Co., Ltd. generates revenue through the manufacture and distribution of radiopharmaceuticals, including diagnostic agents for lung cancer, Parkinson's disease, and Alzheimer's disease. The company produces medical automation modules such as cubes, disposable cassettes, reagent kits, radio-caps, and kryptofix kits, alongside PET and SPECT precursors for radiopharmaceuticals. These products are sold to healthcare providers, diagnostic centers, and medical facilities requiring specialized radiopharmaceutical solutions. The firm also develops metal chelating agents and fluorescence probes for medical applications. The primary buyers of FutureChem's products include hospitals, clinics, and research institutions focused on cancer diagnostics and neurological conditions. Medical automation modules and disposable goods are utilized in diagnostic procedures, while PET and SPECT precursors support imaging technologies. Metal chelating agents and fluorescence probes are integrated into medical testing and imaging processes. FutureChem's revenue streams are driven by the demand for advanced diagnostic tools in oncology and neurology. The company's portfolio targets healthcare segments requiring early detection of diseases, with products designed for both diagnostic imaging and laboratory testing. Sales are concentrated in medical facilities that prioritize precision diagnostics and specialized treatment planning. FutureChem Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about FutureChem Co stock

Free Cash Flow to Debt Ratio of FutureChem Co is -50.10 % in 2024.

Free Cash Flow to Debt Ratio of FutureChem Co changed from -166.79 % to -50.10 %, representing a -69.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio FutureChem Co since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's FutureChem Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — FutureChem Co

All Key Metrics — FutureChem Co